Shopping Cart
- Remove All
- Your shopping cart is currently empty
Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $99 | In Stock | |
5 mg | $245 | In Stock | |
10 mg | $375 | In Stock | |
25 mg | $597 | In Stock | |
50 mg | $885 | In Stock | |
1 mL x 10 mM (in DMSO) | $392 | In Stock |
Description | Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans. |
In vitro | A quantitative structure activity relationship (QSAR) model was developed by a forward stepwise multiple linear regression method to predict the activity of Withanolide Analogs against human breast cancer. The most effective QSAR model for anticancer activity against the SK-Br-3 cell showed the best correlation with activity (r2=0.93 and rCV2 =0.90). Similarly, cross-validation regression coefficient (rCV2=0.85) of the best QSAR model against the MCF7/BUS cells showed a high correlation (r2=0.91). In particular, compounds CID 73621, CID 435144, CID 301751 and CID 3372729 have a marked antiproliferative activity against the MCF7/BUS cells, while 2,3-dihydrowithaferin A-3-beta-O-sulfate, withanolide 5, Withanolide A, withaferin A, CID 10413139, CID 11294368, CID 53477765, CID 135887, CID 301751 and CID 3372729 have a high activity against the Sk-Br-3 cells compared to standard drugs 5-fluorouracil (5-FU) and camptothecin[1] |
Molecular Weight | 470.6 |
Formula | C28H38O6 |
Cas No. | 32911-62-9 |
Smiles | [H][C@@]12CC[C@H]([C@@](C)(O)[C@@]3([H])CC(C)=C(C)C(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H]2O[C@@H]2[C@@]2(O)CC=CC(=O)[C@]12C |
Relative Density. | 1.264 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/ml (116.87 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.